Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
- Cognition and FDA align on enriched population, study design, and endpoints -
How does the sentiment score of 70 reflect market perception, and could it shift after further trial updates?
Will the alignment on endpoints influence the choice of biomarkers and impact trial costs?
What is the expected market size for an approved Alzheimer’s disease treatment and how could Cognition capture share?
9 days ago